Core Insights - CASI Pharmaceuticals has appointed James Huang as an Independent Director, effective October 1, 2025, bringing over 35 years of biotech experience [1] Company Overview - CASI Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for organ transplant rejection and autoimmune diseases [1] Leadership Impact - The appointment of James Huang is expected to significantly enhance the development program of CID-103, an anti-CD38 monoclonal antibody [1]

Financial Performance - Revenues for Q2 2025 were $4.2 million, a 5% increase from $4.0 million in Q2 2024[8] - Revenues for Q2 2025 increased to $4,175,000, up 4.9% from $3,979,000 in Q2 2024[21] - Gross profit for the first half of 2025 was $5,677,000, representing a 46.4% increase compared to $3,873,000 in the same period of 2024[21] - Total operating expenses rose to $13,183,000 in Q2 2025, up 21.4% from $10,856,000 in Q2 2024[21] - Net loss for Q2 2025 was $13.4 million, compared to $7.0 million in Q2 2024[11] - Net loss for Q2 2025 was $13,375,000, compared to a net loss of $6,965,000 in Q2 2024, reflecting a 92.5% increase in losses[21] - Net loss per share for the first half of 2025 was $1.56, compared to $1.23 in the same period of 2024[21] - Total comprehensive loss for the first half of 2025 was $24,591,000, compared to $16,713,000 in the same period of 2024, indicating a significant increase in overall losses[21] Expenses - Cost of revenue for Q2 2025 was $2.1 million, an 11% increase from $1.9 million in Q2 2024[8] - Research and development expenses for Q2 2025 were $1.7 million, up 31% from $1.3 million in Q2 2024, primarily for CID-103 development[9] - Research and development expenses for Q2 2025 were $1,724,000, an increase from $1,254,000 in Q2 2024[21] - Selling and marketing expenses for Q2 2025 were $5.0 million, a 14% increase from $4.4 million in Q2 2024, due to increased marketing efforts[10] - Selling and marketing expenses increased to $4,960,000 in Q2 2025, compared to $4,425,000 in Q2 2024[21] - The company reported a foreign exchange loss of $415,000 in Q2 2025, compared to a gain of $265,000 in Q2 2024[21] Cash Position - Cash and cash equivalents as of June 30, 2025, were $6.7 million, down from $13.5 million as of December 31, 2024[12] Business Developments - The company entered into a definitive agreement to sell 100% equity interests in its Chinese subsidiaries for an aggregate purchase price of $20.0 million[5] - FDA clearance was received for the IND application of CID-103 for antibody-mediated rejection in renal allografts, with a Phase 1 study planned for Q3 2025[3][6] - CID-103 is currently in a Phase 1/2 dose-escalation study for immune thrombocytopenic purpura (ITP)[14] - The company expects to retain rights related to CID-103 in Japan and non-Asian regions after the asset divestiture[7] Shareholder Information - The weighted average number of ordinary shares outstanding increased to 15,505,897 in Q2 2025 from 13,519,328 in Q2 2024[21]

Core Insights - CASI Pharmaceuticals (凯信远达) experienced a stock price increase of 4.03% on August 25, reaching $2.455 per share, with a total market capitalization of $38.0345 million [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, reflecting an 83.04% year-over-year growth, while the net profit attributable to shareholders was -$10.75 million, a decrease of 12.83% year-over-year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focused on providing advanced treatment solutions for blood cancers in Chinese patients [2] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [2] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2]

Core Viewpoint - CASI Pharmaceuticals experienced a significant stock price increase of 10.53% on August 22, reaching $2.52 per share, with a total market capitalization of $39.04 million [1]. Financial Performance - As of March 31, 2025, CASI reported total revenue of $6.24 million, reflecting a year-over-year growth of 83.04% [1]. - The company recorded a net loss attributable to shareholders of $10.75 million, which is a decrease of 12.83% compared to the previous year [1]. Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in Chinese patients [2]. - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [2]. - CASI's product and research pipeline addresses multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2].

Core Viewpoint - CASI Pharmaceuticals (凯信远达) has shown significant revenue growth but continues to report a net loss, indicating potential challenges in profitability despite strong sales performance [1][2]. Financial Performance - As of March 31, 2025, CASI reported total revenue of $6.24 million, representing an 83.04% year-over-year increase [1]. - The company recorded a net loss attributable to shareholders of $10.75 million, which is a 12.83% decrease compared to the previous year [1]. Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in China [2]. - The company has a wholly-owned subsidiary in Beijing and a joint venture and research center in Wuxi, indicating a strong presence in the Chinese market [2]. - CASI's product and research pipeline includes treatments for multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia, among other diseases [2]. Upcoming Events - CASI is scheduled to release its mid-year report for the fiscal year 2025 on August 22, with the actual disclosure date subject to company announcement [2].

Core Viewpoint - CASI Pharmaceuticals (凯信远达) has shown a significant increase in stock price and revenue growth, while still facing challenges with net profit losses [1] Financial Performance - As of March 31, 2025, CASI reported total revenue of $6.24 million, representing a year-over-year increase of 83.04% [1] - The company recorded a net loss attributable to shareholders of $10.75 million, which is a decrease of 12.83% compared to the previous year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focusing on advanced treatment solutions for blood cancers in Chinese patients [1] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [1] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [1]

Core Viewpoint - CASI Pharmaceuticals, a U.S.-listed biopharmaceutical company, is focused on providing advanced treatment solutions for blood cancers in China, showing significant revenue growth but facing net loss challenges [1]. Financial Performance - As of March 31, 2025, CASI reported total revenue of $6.24 million, representing a year-over-year increase of 83.04% [1]. - The company experienced a net loss attributable to shareholders of $10.75 million, which is a decrease of 12.83% compared to the previous year [1]. Company Overview - CASI Pharmaceuticals is headquartered in Rockville, Maryland, and has a wholly-owned subsidiary in Beijing, along with a joint venture and R&D center in Wuxi [1]. - The company's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [1].

Core Insights - CASI Pharmaceuticals (凯信远达) experienced a stock price increase of 2.94%, reaching $2.45 per share, with a total market capitalization of $37.96 million as of August 18 [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, reflecting a year-over-year growth of 83.04%, while the net profit attributable to shareholders was a loss of $10.75 million, a decrease of 12.83% compared to the previous year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focusing on advanced treatment solutions for blood cancers in Chinese patients [1] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi in collaboration with local governments [1] - CASI's product and research pipeline addresses multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [1]

Core Insights - CASI Pharmaceuticals (凯信远达) experienced a stock price increase of 5.67% on August 16, reaching $2.05 per share, with a total market capitalization of $31.76 million [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, reflecting a year-over-year growth of 83.04%, while the net profit attributable to shareholders was a loss of $10.75 million, a decrease of 12.83% compared to the previous year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focused on providing advanced treatment solutions for blood cancers in Chinese patients [2] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi, China [2] - CASI's product and research pipeline addresses multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2]

Core Viewpoint - CASI Pharmaceuticals reported significant revenue growth but continued to face net losses, indicating a mixed financial performance as it expands its operations in the oncology sector [1][2]. Financial Performance - As of March 31, 2025, CASI's total revenue reached $6.24 million, reflecting an 83.04% year-over-year increase [1]. - The company's net profit attributable to shareholders was -$10.75 million, which represents a 12.83% decrease compared to the previous year [1]. Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in China [2]. - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi, covering multiple disease areas including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2].